LEXX Message Board Post 10865206 | Lexaria Bioscience Corp.
home / stock / lexx / lexx message board
timothylw
(investorshangout)
Posted on: Dec/29/2022 20:22:44
Source: investorshangout
https://investorshangout.com/post/view?id=6516655
NetworkNewsWire: NetworkNewsBreaks Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures 28th Patent in International
News, Short Squeeze, Breakout and More Instantly...
-
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
-
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
-
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...